SpeciousNews| hong kong

hong kong

Youre Likely to Get the Coronavirus -13%

In May 1997, a 3-year-old boy developed what at first seemed like the common cold. When his symptoms—sore throat, fever, and cough—persisted for six days, he was taken to the Queen Elizabeth Hospital in Hong Kong. There his cough worsened, and he began gasping for air. Despite intensive care, the boy died.

Puzzled by his rapid deterioration, doctors sent a sample of the boy’s sputum to China’s Department of Health. But the standard testing protocol couldn’t fully identify the virus that had caused the disease. The chief virologist decided to ship some of the sample to colleagues in other countries.

At the U.S. Centers for Disease Control and Prevention in Atlanta, the boy’s sputum sat for a month, waiting for its turn in a slow process of antibody-matching analysis. The results eventually confirmed that this was a variant of influenza, the virus that has killed more people than any in history. But this type had never before been seen in humans. It was H5N1, or “avian flu,” discovered two decades prior, but known only to infect birds.

By then, it was August. Scientists sent distress signals around the world. The Chinese government swiftly killed 1.5 million chickens (over the protests of chicken farmers). Further cases were closely monitored and isolated. By the end of the year there were 18 known cases in humans. Six people died.

This was seen as a successful global response, and the virus was not seen again for years. In part, containment was possible because the disease was so severe: Those who got it became manifestly, extremely ill. H5N1 has a fatality rate of around 60 percent—if you get it, you’re likely to die. Yet since 2003, the virus has killed only 455 people. The much “milder” flu viruses, by contrast, kill fewer than 0.1 percent of people they infect, on average, but are responsible for hundreds of thousands of deaths every year.

Severe illness caused by viruses such as H5N1 also means that infected people can be identified and isolated, or that they died quickly. They do not walk around feeling just a little under the weather, seeding the virus. The new coronavirus (known technically as SARS-CoV-2) that has been spreading around the world can cause a respiratory illness that can be severe. The disease (known as COVID-19) seems to have a fatality rate of less than 2 percent—exponentially lower than most outbreaks that make global news. The virus has raised alarm not despite that low fatality rate, but because of it.

Coronaviruses are similar to influenza viruses in that they are both single strands of RNA. Four coronaviruses commonly infect humans, causing colds. These are believed to have evolved in humans to maximize their own spread—which means sickening, but not killing, people. By contrast, the two prior novel coronavirus outbreaks—SARS (severe acute respiratory syndrome) and MERS (Middle East respiratory syndrome, named for where the first outbreak occurred)—were picked up from animals, as was H5N1. These diseases were highly fatal to humans. If there were mild or asymptomatic cases, they were extremely few. Had there been more of them, the disease would have spread widely. Ultimately, SARS and MERS each killed fewer than 1,000 people.

COVID-19 is already reported to have killed more than twice that number. With its potent mix of characteristics, this virus is unlike most that capture popular attention: It is deadly, but not too deadly. It makes people sick, but not in predictable, uniquely identifiable ways. Last week, 14 Americans tested positive on a cruise ship in Japan despite feeling fine—the new virus may be most dangerous because, it seems, it may sometimes cause no symptoms at all.

[Read: The new coronavirus is a truly modern epidemic]

The world has responded with unprecedented speed and mobilization of resources. The new virus was identified extremely quickly. Its genome was sequenced by Chinese scientists and shared around the world within weeks. The global scientific community has shared genomic and clinical data at unprecedented rates. Work on a vaccine is well under way. The Chinese government enacted dramatic containment measures, and the World Health Organization declared an emergency of international concern. All of this happened in a fraction of the time it took to even identify H5N1 in 1997. And yet the outbreak continues to spread.

The Harvard epidemiology professor Marc Lipsitch is exacting in his diction, even for an epidemiologist. Twice in our conversation he started to say something, then paused and said, “Actually, let me start again.” So it’s striking when one of the points he wanted to get exactly right was this: “I think the likely outcome is that it will ultimately not be containable.”

Containment is the first step in responding to any outbreak. In the case of COVID-19, the possibility (however implausible) of preventing a pandemic seemed to play out in a matter of days. Starting in January, China began cordoning off progressively larger areas, radiating outward from Wuhan City and eventually encapsulating some 100 million people. People were barred from leaving home, and lectured by drones if they were caught outside. Nonetheless, the virus has now been found in 24 countries.

Despite the apparent ineffectiveness of such measures—relative to their inordinate social and economic cost, at least—the crackdown continues to escalate. Under political pressure to “stop” the virus, last Thursday the Chinese government announced that officials in the Hubei province would be going door to door, testing people for fevers and looking for signs of illness, then sending all potential cases to quarantine camps. But even with the ideal containment, the virus’s spread may have been inevitable. Testing people who are already extremely sick is an imperfect strategy if people can spread the virus without even feeling bad enough to stay home from work.

Lipsitch predicts that, within the coming year, some 40 to 70 percent of people around the world will be infected with the virus that causes COVID-19. But, he clarifies emphatically, this does not mean that all will have severe illnesses. “It’s likely that many will have mild disease, or may be asymptomatic,” he said. As with influenza, which is often life-threatening to people with chronic health conditions and of older age, most cases pass without medical care. (Overall, around 14 percent of people with influenza have no symptoms.)

Lipsitch is far from alone in his belief that this virus will continue to spread widely. The emerging consensus among epidemiologists is that the most likely outcome of this outbreak is a new seasonal disease—a fifth “endemic” coronavirus. With the other four, people are not known to develop long-lasting immunity. If this one follows suit, and if the disease continues to be as severe as it is now, “cold and flu season” could become “cold and flu and COVID-19 season.”

At this point, it is not even known how many people are infected. As of Sunday, there have been 35 confirmed cases in the U.S., according to the World Health Organization. But Lipsitch’s “very, very rough” estimate when we spoke a week ago (banking on “multiple assumptions piled on top of each other,” he said) was that 100 or 200 people in the U.S. were infected. That’s all it would take to seed the disease widely. The rate of spread would depend on how contagious the disease is in milder cases. On Friday, Chinese scientists reported in the medical journal JAMA an apparent case of asymptomatic spread of the virus, from a patient with a normal chest CT scan. The researchers concluded with stolid understatement that if this finding is not a bizarre abnormality, “the prevention of COVID-19 infection would prove challenging.”

[Read: 20 seconds to optimize hand wellness]

Even if Lipsitch’s estimates were off by orders of magnitude, they wouldn’t likely change the overall prognosis. “Two hundred cases of a flu-like illness during flu season—when you’re not testing for it—is very hard to detect,” Lipsitch said. “But it would be really good to know sooner rather than later whether that’s correct, or whether we’ve miscalculated something. The only way to do that is by testing.”

Originally, doctors in the U.S. were advised not to test people unless they had been to China or had contact with someone who had been diagnosed with the disease. Within the past two weeks, the CDC said it would start screening people in five U.S. cities, in an effort to give some idea of how many cases are actually out there. But tests are still not widely available. As of Friday, the Association of Public Health Laboratories said that only California, Nebraska, and Illinois had the capacity to test people for the virus.

With so little data, prognosis is difficult. But the concern that this virus is beyond containment—that it will be with us indefinitely—is nowhere more apparent than in the global race to find a vaccine, one of the clearest strategies for saving lives in the years to come.

Over the past month, stock prices of a small pharmaceutical company named Inovio more than doubled. In mid-January, it reportedly discovered a vaccine for the new coronavirus. This claim has been repeated in many news reports, even though it is technically inaccurate. Like other drugs, vaccines require a long testing process to see if they indeed protect people from disease, and do so safely. What this company—and others—has done is copy a bit of the virus’s RNA that one day could prove to work as a vaccine. It’s a promising first step, but to call it a discovery is like announcing a new surgery after sharpening a scalpel.

Though genetic sequencing is now extremely fast, making vaccines is as much art as science. It involves finding a viral sequence that will reliably cause a protective immune-system memory but not trigger an acute inflammatory response that would itself cause symptoms. (While the influenza vaccine cannot cause the flu, CDC warns that it can cause “flu-like symptoms.”) Hitting this sweet spot requires testing, first in lab models and animals, and eventually in people. One does not simply ship a billion viral gene fragments around the world to be injected into everyone at the moment of discovery.

Inovio is far from the only small biotech company venturing to create a sequence that strikes that balance. Others include Moderna, CureVac, and Novavax. Academic researchers are also on the case, at Imperial College London and other universities, as are federal scientists in several countries, including at the U.S. National Institutes of Health. Anthony Fauci, head of the NIH’s National Institute of Allergy and Infectious Diseases, wrote in JAMA in January that the agency was working at historic speed to find a vaccine. During the SARS outbreak in 2003, researchers moved from obtaining the genomic sequence of the virus and into a phase 1 clinical trial of a vaccine in 20 months. Fauci wrote that his team has since compressed that timeline to just over three months for other viruses, and for the new coronavirus, “they hope to move even faster.”

New models have sprung up in recent years, too, that promise to speed up vaccine development. One is the Coalition for Epidemic Preparedness (CEPI), which was launched in Norway in 2017 to finance and coordinate the development of new vaccines. Its founders include the governments of Norway and India, the Wellcome Trust, and the Bill & Melinda Gates Foundation. The group’s money is now flowing to Inovio and other small biotech start-ups, encouraging them to get into the risky business of vaccine development. The group’s CEO, Richard Hatchett, shares Fauci’s basic timeline vision—a COVID-19 vaccine ready for early phases of safety testing in April. If all goes well, by late summer testing could begin to see if the vaccine actually prevents disease.

[Read: Coronavirus is devastating Chinese tourism]

Overall, if all pieces fell into place, Hatchett guesses it would be 12 to 18 months before an initial product could be deemed safe and effective. That timeline represents “a vast acceleration compared with the history of vaccine development,” he told me. But it’s also unprecedentedly ambitious. “Even to propose such a timeline at this point must be regarded as hugely aspirational,” he added.

Even if that idyllic year-long projection were realized, the novel product would still require manufacturing and distribution. “An important consideration is whether the underlying approach can then be scaled to produce millions or even billions of doses in coming years,” Hatchett said. Especially in an ongoing emergency, if borders closed and supply chains broke, distribution and production could prove difficult purely as a matter of logistics.

Fauci’s initial optimism seemed to wane, too. Last week he said that the process of vaccine development was proving “very difficult and very frustrating.” For all the advances in basic science, the process cannot proceed to an actual vaccine without extensive clinical testing, which requires manufacturing many vaccines and meticulously monitoring outcomes in people. The process could ultimately cost hundreds of millions of dollars—money that the NIH, start-ups, and universities don’t have. Nor do they have the production facilities and technology to mass-manufacture and distribute a vaccine.

Production of vaccines has long been contingent on investment from one of the handful of giant global pharmaceutical companies. At the Aspen Institute last week, Fauci lamented that none had yet to “step up” and commit to making the vaccine. “Companies that have the skill to be able to do it are not going to just sit around and have a warm facility, ready to go for when you need it,” he said. Even if they did, taking on a new product like this could mean massive losses, especially if the demand faded or if people, for complex reasons, chose not to use the product.

Making vaccines is so difficult, cost intensive, and high risk that in the 1980s, when drug companies began to incur legal costs over alleged harms caused by vaccines, many opted to simply quit making them. To incentivize the pharmaceutical industry to keep producing these vital products, the U.S. government offered to indemnify anyone claiming to have been harmed by a vaccine. The arrangement continues to this day. Even still, drug companies have generally found it more profitable to invest in the daily-use drugs for chronic conditions. And coronaviruses could present a particular challenge in that at their core they are, like influenza viruses, a single strand of RNA. This viral class is likely to mutate, and vaccines may need to be in constant development, as with the flu.

“If we’re putting all our hopes in a vaccine as being the answer, we’re in trouble,” Jason Schwartz, an assistant professor at Yale School of Public Health who studies vaccine policy, told me. The best-case scenario, as Schwartz sees it, is the one in which this vaccine development happens far too late to make a difference for the current outbreak. The real problem is that preparedness for this outbreak should have been happening for the past decade, ever since SARS. “Had we not set the SARS-vaccine-research program aside, we would have had a lot more of this foundational work that we could apply to this new, closely related virus, ” he said. But, as with Ebola, government funding and pharmaceutical-industry development evaporated once the sense of emergency lifted. “Some very early research ended up sitting on a shelf because that outbreak ended before a vaccine needed to be aggressively developed.”

On Saturday, Politico reported that the White House is preparing to ask Congress for $1 billion in emergency funding for a coronavirus response. This request, if it materialized, would come in the same month in which President Donald Trump released a new budget proposal that would cut key elements of pandemic preparedness—funding for the CDC, the NIH, and foreign aid.

[Read: It’s suddenly cold out. Am I going to get sick?]

These long-term government investments matter because creating vaccines, antiviral medications, and other vital tools requires decades of serious investment, even when demand is low. Market-based economies often struggle to develop a product for which there is no immediate demand and to distribute products to the places they’re needed. CEPI has been touted as a promising model to incentivize vaccine development before an emergency begins, but the group also has skeptics. Last year, Doctors Without Borders wrote a scathing open letter, saying the model didn’t ensure equitable distribution or affordability. CEPI subsequently updated its policies to forefront equitable access, and Manuel Martin, a medical innovation and access adviser with Doctors Without Borders, told me last week that he’s now cautiously optimistic. “CEPI is absolutely promising, and we really hope that it will be successful in producing a novel vaccine,” he said. But he and his colleagues are “waiting to see how CEPI’s commitments play out in practice.”

These considerations matter not simply as humanitarian benevolence, but also as effective policy. Getting vaccines and other resources to the places where they will be most helpful is essential to stop disease from spreading widely. During the 2009 H1N1 flu outbreak, for example, Mexico was hit hard. In Australia, which was not, the government prevented exports by its pharmaceutical industry until it filled the Australian government’s order for vaccines. The more the world enters lockdown and self-preservation mode, the more difficult it could be to soberly assess risk and effectively distribute tools, from vaccines and respirator masks to food and hand soap.

Italy, Iran, and South Korea are now among the countries reporting quickly growing numbers of detected COVID-19 infections. Many countries have responded with containment attempts, despite the dubious efficacy and inherent harms of China’s historically unprecedented crackdown. Certain containment measures will be appropriate, but widely banning travel, closing down cities, and hoarding resources are not realistic solutions for an outbreak that lasts years. All of these measures come with risks of their own. Ultimately some pandemic responses will require opening borders, not closing them. At some point the expectation that any area will escape effects of COVID-19 must be abandoned: The disease must be seen as everyone’s problem.

Fearing coronavirus, Hong Kong's 'coffin home' dwellers stay indoors -12%

To escape the confines of his Hong Kong "coffin home", or two square meters (21.5 square feet) of living space, Simon Wong usually spends his days in the park playing mahjong with friends, only returning at night to sleep.

Hong Kong government extends school suspension amid coronavirus outbreak -7%

Hong Kong has further extended the suspension of schools until at least April 20 to contain the spread of the coronavirus, authorities in the Asian financial hub said on Tuesday as cases of the

KPMG to axe 40 jobs, or 2 per cent of Hong Kong headcount, as it remodels its advisory business to embrace tech innovation 9%

KPMG, one of the world’s four largest accounting firms and professional services network, will make 40 jobs redundant at its advisory business in Hong Kong as it remodels its consultancy operation, according to two people familiar with the plans.The staff affected, representing 2 per cent of the firm’s headcount in Hong Kong and 4 per cent of the positions in the advisory business, will be let go in the coming days, according to the sources, who declined to be named for speaking of a…

Hong Kong is poised for another real estate crisis as falling home prices drive more mortgage borrowers into negative equity -22%

Hong Kong’s commercial banks are cutting their valuations of mortgaged homes as they bow to the double whammy impact of a viral epidemic with months of anti-government protests, in a move that could drive even more borrowers into negative equity and provoke panic selling.The weekly Centa Valuation Index (CVI) compiled by one of the biggest real estate agencies in the city plummeted by 3.52 points to 12.5 last week, the lowest level since January 2019. The lower the reading, the more bearish…

Number of coronavirus cases in Hong Kong could surge to more than 1,000 in next two weeks, scientist claims 20%

The number of coronavirus cases in Hong Kong could balloon to more than 1,000 within the next two weeks if the government does not effectively manage the epidemic, a local scientist has claimed.Dr Sean Yuan Hsiang-yu, an assistant professor at City University’s Department of Biomedical Sciences, said the risk of a community outbreak was medium high to very high, depending on the quality of quarantine measures, as well as delay between the onset of sickness and isolation.“We have seen in recent…

Five suspected drug traffickers arrested in Hong Kong and HK$35 million worth of crystal meth, ketamine and cocaine seized in four separate busts -9%

Five suspected drug traffickers were arrested and HK$35.7 million (US$4.6 million) worth of illegal drugs seized in four separate cases in two days, Hong Kong law enforcers said on Tuesday. Four of the suspects were picked up at Hong Kong International Airport with 25.5kg of crystal meth, ketamine and cocaine hidden in their suitcases when they arrived from Paris, Greece and Thailand. The fifth suspect was caught with the seizure of HK$19 million worth of cocaine hidden in luggage at a…

Coronavirus: 18 Hongkongers back from South Korea sent to quarantine on return, hundreds more still travelling in the country -15%

At least 18 Hong Kong residents returning from South Korea were sent to 14-day quarantine at a housing estate on Tuesday night, while hundreds still in tour groups in the country could face the same fate under new coronavirus control measures now in effect.The returnees, 17 Hong Kong travellers and a tour guide for Sunflower Travel Service who had been on a five-day tour of South Korea, were taken by health officers to Chun Yeung Estate in Fo Tan for the compulsory quarantine after they arrived…

Hong Kong exports record worst drop in decade as economist warns worst is yet to come -33%

Hong Kong exports recorded the worst drop in a decade in January, down almost 23 per cent, as the government warned of a very tough trading environment in the next few months.The value of total exports of goods plunged by 22.7 per cent over a year ago to HK$269.4 billion, after a year-on-year increase of 3.3 per cent in December, the Census and Statistics Department said on Tuesday.This was the biggest drop since August 2009 when it was down by 32 per cent.The imports of goods also dropped 16.4…

Coronavirus: missing meals, no toilet paper, and leaks, but for some Hong Kong quarantine is heaven compared with luxury hell of Diamond Princess cruise -7%

Six days into their mandatory quarantine period and the Hong Kong passengers evacuated from the Diamond Princess cruise ship in Japan are experiencing wildly different emotions.For some of those being held on Chun Yeung Estate time is hanging heavy, and a lack of meals, toilet paper, and other basic necessities is taking its toll.But others have described the public housing estate in Fo Tan as an “unadorned heaven” and are just grateful to be free of the “luxury hell” of the ship, and the daily…

Coronavirus in Hong Kong: MTR Corps passenger numbers plummet amid outbreak 6%

Hong Kong’s coronavirus outbreak has brought a steep fall in January passenger numbers for a city rail operator already battered by months of anti-government unrest, with observers warning of even more hard times ahead.According to the latest figures from the MTR Corporation, ridership on domestic services was 116.5 million in January, down 21 per cent year on year.Its high-speed link to mainland China recorded the biggest drop in traveller numbers – down almost 40 per cent to 1.05 million,…

Hong Kong sex attacker groped 10 women when pretending to brush off insects, say police who arrest man, 29

A serial sex attacker groped 10 women in Hong Kong on the pretence of brushing insects off them, according to police who have arrested a 29-year-old man.Officers raided the construction worker’s home in Kam Fung Court, Ma On Shan, at 7.30am on Monday and held him on suspicion of indecent assault and theft.As of Tuesday morning, the suspect was being questioned at Sha Tin Police Station and had not been charged.Doctor convicted of indecent assault spared jail after court shows mercyPolice said…

China jails Hong Kong bookseller Gui Minhai for 10 years -5%

A Chinese court has convicted Hong Kong bookseller Gui Minhai for “illegally providing intelligence for overseas entities”, almost five years after he was first detained.Gui was sentenced to 10 years and deprivation of political rights for five years by a Chinese court on Monday. A statement by the Intermediate People’s Court of Ningbo said Gui would not appeal at the end of the trial.Gui, a Swedish national, ran Causeway Bay Books in Hong Kong – an outlet known for selling gossipy titles about…

Coronavirus: Hong Kong schools to remain closed until after Easter but university entrance exams set to go ahead as planned in March -3%

After being shut for more than three weeks, Hong Kong schools are to remain closed until after Easter even as university entrance exams will go ahead as planned, education officials said on Tuesday, as four more cases of the coronavirus infection were reported, taking the total to 85.Announcing the further school closure, Secretary for Education Kevin Yeung Yun-hung said classes at all kindergartens, primary and secondary schools would be suspended until April 20 at the earliest, confirming an…

Coronavirus: Hong Kong Jockey Club member the latest confirmed case, bringing total in city to 85 12%

A fourth coronavirus case was confirmed in Hong Kong late on Tuesday, a 60-year-old member of the Jockey Club, increasing the city’s total number of infections to 85.The woman, who lives in Tai Hang on Hong Kong Island, had consulted a private doctor five times before she was transferred to the private Hong Kong Sanatorium and Hospital in Happy Valley.She previously visited Man Mo Temple in Sheung Wan, attended a wedding and went to galleries, among others.That came as Chief Executive Carrie…

Coronavirus: has Hong Kong learned the hard lessons of Sars or is it repeating the same mistakes? 28%

After the Sars outbreak of 2003 claimed 299 lives in Hong Kong, a postmortem of the city’s missteps held a handful of senior officials accountable. The most high profile figure was health minister Yeoh Eng-kiong.A Legislative Council report in 2004 found Yeoh responsible for a catalogue of failings, including insufficient communication with the public, poor supervision of the health department, and inadequate monitoring of the Hospital Authority, which did not have a contingency plan for large…

Coronavirus: Beijings top official in Hong Kong makes email plea for unity, reassures city over supplies 25%

Beijing’s top envoy in Hong Kong has written to pro-Beijing politicians in the city appealing to them for unity with mainland China in battling the coronavirus, and criticising those he said were using the crisis for political self-interest.Luo Huining, the new director of Beijing’s liaison office in Hong Kong, on Thursday sent a letter by email to local members of the National People’s Congress (NPC), China’s legislature, and top legislative advisory body the Chinese People’s Political…

Beijings man in Hong Kong enlists China-backed businesses in coronavirus battle

Beijing’s top envoy in Hong Kong has called on China-funded businesses to help ensure market stability in the city, especially for daily necessities, and offer financial relief to local businesses reeling from the coronavirus outbreak.Luo Huining, director of the central government’s liaison office in Hong Kong, issued the call on Monday as he visited a number of major Chinese enterprises in the city including Bank of China, China Merchants Group, China Resources and Sinopec, according to a…

Prudential should move Asian headquarters to Hong Kong, urges second-largest shareholder Third Point -8%

Prudential should break itself up into two publicly listed companies focused on Asia and the US to boost shareholder value, urged activist investor Third Point.The London-headquartered insurer should then move the primary base for its Asian arm to Hong Kong, and that of its US business, Jackson National Life, to Michigan, said Third Point. It should also stop prioritising dividends over investment in Asia.This deep restructuring would unleash the potential of its fastest-growing business,…

Hong Kong, China stocks pressured by concerns coronavirus is spreading beyond China 31%

Good day, traders -- Bargain hunting pushed some Hong Kong stocks up in afternoon trading. The Shanghai Composite Index declined. Check out the day's action below. And if you would like the Live Stocks Blog emailed to you each morning, click here. -- Kathleen Magramo and Deb Price in Hong Kong Note: Information in this blog is on an "as is" basis and not a solicitation or offer to buy or sell any securities or otherwise; and is not investment/professional advice or services in this…

Worse than financial crisis, deadlier than Sars: coronavirus to push Hong Kong bankruptcies to decade high -11%

Hong Kong is poised to see the biggest jump in more than a decade in personal bankruptcies and companies winding up this year, as individuals and firms are overwhelmed by “multiple problems” that are far worse than any crisis seen previously, according to the Hong Kong Institute of Certified Public Accountants.“I expect the situation will be worse than previous crises such as Sars (Severe Acute Respiratory Syndrome) in 2003 because we are facing multiple problems which have been dragging on for…

Hong Kong stocks clobbered as fears grow about global spread of coronavirus 35%

Welcome to a fresh week, traders! The coronavirus is spreading in Italy and South Korea, raising alarms. That hurt sentiment in Hong Kong and mainland markets. Catch up on the day's action below. And if you would like the Live Stocks Blog emailed to you each morning, click here. -- Iris Ouyang, Kathleen Magramo and Deb Price in Hong Kong Note: Information in this blog is on an "as is" basis and not a solicitation or offer to buy or sell any securities or otherwise; and is not investment…

Ignore short-term noise like coronavirus, Hong Kong protests and focus on US health care stocks, says Charles Schwab -1%

Investors should dismiss “short-term noise” like the anti-government protests that have rocked Hong Kong and the outbreak of coronavirus if they want their portfolio to work for them in the long run, according to Charles Schwab.The American bank and brokerage recommended US health care stocks as the only reliable long-term investment.The civil unrest that has crippled Hong Kong’s economy and the current Covid-19 crisis are merely “noise” in the market and investors should not let “knee-jerk…

Hong Kongs super-rich need more money managers, investment specialists as crisis, evolving trends threaten talent gap: survey 17%

Hong Kong has the second largest number of billionaires in the world and the most millionaires in the region. For all the US$3.25 trillion of investable wealth, though, the pool of money managers and investment advisers is not growing fast enough.The talent gap is among the biggest challenges facing the city in the private wealth management industry, according to a survey conducted by the Financial Services Development Council, a government-funded body tasked with promoting the sector.The view…

Big business is stepping up where the Hong Kong government has fallen short in the coronavirus fight, but it can do more 1%

The Hong Kong government has stumbled from one crisis to another, and its handling of the coronavirus public health emergency has laid bare the incompetence, insensitivity and lack of preparedness of those who, in theory, lead what they boast to be “Asia’s world city”. With public trust in the Carrie Lam administration hollowed out following months of bruising anti-government protests in 2019, there has been a considerable display of resourcefulness, resilience and solidarity among the public…